Pegozafermin Led to Significant Metabolic Benefits, in Addition to Robust Beneficial Effects on the Liver, in an Open-label Cohort of a Phase 1b/2a Study in Subjects with Non-alcoholic Steatohepatitis (NASH)
- Resource Type
- Source
- Metabolism. 142:155455
- Subject
Endocrinology Endocrinology, Diabetes and Metabolism - Language
- ISSN
- 0026-0495